These are among the best-evidenced compounds discussed in physique contexts, with large randomised trials for weight reduction. The risks in this setting come from lean mass loss, unsupervised dose escalation and compounded or grey-market product of unknown identity.
Key points
- Large randomised trials establish substantial weight reduction with semaglutide and tirzepatide in people with obesity.
- A meaningful share of the weight lost is lean tissue unless resistance training and protein intake are maintained.
- Gastrointestinal effects are common; gallbladder disease and pancreatitis are recognised, less frequent concerns.
- Grey-market and compounded vials have been associated with dosing errors and unverified contents.
What the literature shows
The STEP programme reported mean weight reductions substantially greater than placebo with once-weekly semaglutide over 68 weeks, alongside improvements in cardiometabolic markers.
SURMOUNT trials reported larger reductions with tirzepatide, a dual GIP/GLP-1 receptor agonist, over comparable durations.
Body-composition substudies indicate that lean mass declines alongside fat mass, in proportions broadly consistent with other weight-loss interventions.
Reports describe dosing errors where users measured from multi-dose vials rather than pre-filled devices, including tenfold overdoses requiring hospital care.
What remains unknown
- Effects of intermittent, physique-driven use in lean, trained individuals are not studied.
- Long-term consequences of repeated weight loss and regain cycles with these drugs are unclear.
- Content and sterility of grey-market vials cannot be assumed, and outcomes from that supply chain are undocumented.
Safety and monitoring implications
- Dosing errors are a leading documented harm outside clinical supply; unit confusion between millilitres, milligrams and syringe units is the common pattern.
- Persistent vomiting, severe abdominal pain radiating to the back, or right upper-quadrant pain warrant urgent medical review.
- Resistance training and adequate protein reduce, but do not eliminate, lean mass loss.
Cited literature
- 1.Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. Find on PubMed
- 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. Find on PubMed
- 3.Ida S, Kaneko R, Imataka K, et al. (2021). Effects of glucagon-like peptide-1 receptor agonists on muscle mass and strength. Journal of Clinical Medicine. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Australian physique and dieting forums
MixedAppetite suppression is described as dramatic and effective, with frequent complaints of low training energy and strength loss during use.
Harm-reduction discussion groups
NegativeRepeated warnings about measuring doses from research vials, with several accounts of accidental large overdoses and days of vomiting.
Buying Semaglutide / tirzepatide in Australia: what to check first
APEDRA does not sell Semaglutide / tirzepatide or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.